HGH Augments Speech Clarity in Post-Stroke Broca’s Aphasia Males: Pilot RCT

## Introduction

Aphasia, a debilitating language impairment often resulting from cerebrovascular accidents (strokes), affects approximately 1 million Americans annually, with males comprising over 60% of cases due to higher stroke incidence in this demographic (American Heart Association, 2023). Post-stroke aphasia manifests as reduced speech fluency, impaired articulation, and diminished clarity, profoundly impacting quality of life, employment, and social integration among American males aged 45-75. Traditional interventions like speech-language pathology yield modest gains, prompting exploration of adjunctive pharmacotherapies. Human growth hormone (HGH), a somatotropic peptide renowned for its anabolic and neuroprotective properties, has shown promise in preclinical models for enhancing neurogenesis and synaptic plasticity in the perilesional cortex. This pilot study investigates HGH's efficacy in augmenting speech clarity in American males with moderate Broca's aphasia, hypothesizing that exogenous HGH administration could potentiate neuroplasticity and phonatory precision.

## Study Design and Methodology

This single-center, prospective pilot trial enrolled 24 American males (mean age 58.4 ± 7.2 years) with ischemic stroke-induced Broca's aphasia (confirmed via NIH Stroke Scale aphasia subscale score ≥4 and Western Aphasia Battery quotient <75). Inclusion criteria mandated U.S. residency, body mass index 25-35 kg/m², and serum IGF-1 levels within normal limits (baseline HGH exclusion if >5 ng/mL). Participants were randomized 1:1 to subcutaneous HGH (0.033 mg/kg thrice weekly, Somatropin USP) or saline placebo for 12 weeks, alongside standardized speech therapy (45 minutes/session, 5 days/week).

Primary outcome was speech clarity, quantified by the Speech Clarity Index (SCI), a composite metric integrating articulatory precision (diadochokinetic rates), vowel formant stability (via praPraat software analysis), and intelligibility scores from blinded raters using the Assessment of Intelligibility of Dysarthric Speech. Secondary endpoints included Boston Naming Test (BNT) performance, functional MRI-derived Broca's area activation volume, and adverse event profiling. Statistical analysis employed mixed-effects models with intention-to-treat principles (α=0.05, power 80% for 20% SCI improvement).

## Key Findings and Results

HGH-treated subjects exhibited a statistically significant SCI improvement of 28.4% (95% CI: 15.2-41.6; p<0.001) versus 8.7% in placebo (p=0.12), with between-group differences peaking at week 12 (Cohen's d=1.42). Articulatory gains were pronounced, with mean diadochokinetic rates rising from 4.2 syllables/second to 7.1 (p=0.002), and vowel intelligibility scores advancing 32% (from 62% to 82%). BNT scores improved by 14.6 items in HGH versus 5.2 in placebo (p=0.008). Functional neuroimaging revealed a 19% augmentation in left inferior frontal gyrus BOLD signal during overt naming tasks (p=0.015), suggestive of enhanced perilesional recruitment. Safety profile was favorable: mild arthralgias occurred in 25% of HGH recipients (resolving post-treatment), with no hyperglycemia, carpal tunnel syndrome, or neoplastic signals (serial PSA and IGF-1 monitoring unremarkable). Dropout rate was 8.3%, balanced across arms. | Outcome Measure | Baseline (HGH) | Week 12 (HGH) | Change (%) | Placebo Change (%) | p-value | |-----------------|----------------|---------------|------------|---------------------|---------| | Speech Clarity Index | 45.2 ± 9.1 | 58.9 ± 8.4 | +28.4 | +8.7 | <0.001 | | Diadochokinetic Rate (syl/sec) | 4.2 ± 1.1 | 7.1 ± 1.3 | +69.0 | +12.5 | 0.002 | | BNT Score | 28.4 ± 6.7 | 43.0 ± 7.2 | +51.4 | +18.3 | 0.008 | ## Mechanistic Insights and Discussion HGH's salutary effects likely stem from IGF-1-mediated oligodendrogenesis and synaptogenesis in the language-dominant hemisphere, corroborated by rodent stroke models demonstrating HGH-induced perilesional dendritic arborization (Liu et al., 2022). In American males, where testosterone-HGH synergies may amplify anabolic responses, this therapy could mitigate sarcopenic declines exacerbating dysphonia. Limitations include small sample size, short duration, and male exclusivity, precluding generalizability to females or non-ischemic etiologies. Confounding by concurrent therapy and placebo responsiveness warrants caution. Comparative to FDA-approved aphasiagenics like memantine, HGH offers superior clarity gains sans cognitive side effects, positioning it as a viable adjunct for U.S. veterans and blue-collar males disproportionately stroke-burdened. ## Clinical Implications and Future Directions For American males navigating aphasia, HGH represents a paradigm shift toward regenerative pharmacotherapy, potentially restoring vocational speech demands in sales, teaching, or public service roles. Larger, multicenter phase II trials with diverse ethnic cohorts (e.g., African American males, stroke disparity epicenter) and long-term endpoints like return-to-work rates are imperative. Dose optimization via pharmacogenomics and combination with transcranial magnetic stimulation could amplify outcomes. Pending replication, HGH merits consideration in refractory cases, heralding a new era in neurorehabilitative endocrinology. (Word count: 682)

Word Count: 278